Gedeon Richter (RIG2) Stock Overview
Researches, develops, manufactures, markets, and sells pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
RIG2 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Gedeon Richter PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Ft32.94 |
| 52 Week High | Ft33.26 |
| 52 Week Low | Ft24.50 |
| Beta | 0.26 |
| 1 Month Change | 10.61% |
| 3 Month Change | 24.68% |
| 1 Year Change | 29.18% |
| 3 Year Change | 61.47% |
| 5 Year Change | 40.05% |
| Change since IPO | 407.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| RIG2 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 6.2% | 1.3% | 2.9% |
| 1Y | 29.2% | 25.4% | 12.1% |
Return vs Industry: RIG2 exceeded the German Pharmaceuticals industry which returned 25.4% over the past year.
Return vs Market: RIG2 exceeded the German Market which returned 12.1% over the past year.
Price Volatility
| RIG2 volatility | |
|---|---|
| RIG2 Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.7% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: RIG2 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: RIG2's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1901 | 10,943 | Gabor Orban | www.gedeonrichter.com |
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. The company offers women’s healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids, as well as Femtech, a digital therapeutic solution to enhance women’s lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases.
Gedeon Richter PLC Fundamentals Summary
| RIG2 fundamental statistics | |
|---|---|
| Market cap | €6.23b |
| Earnings (TTM) | €619.95m |
| Revenue (TTM) | €2.48b |
Is RIG2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RIG2 income statement (TTM) | |
|---|---|
| Revenue | Ft928.96b |
| Cost of Revenue | Ft288.05b |
| Gross Profit | Ft640.91b |
| Other Expenses | Ft408.58b |
| Earnings | Ft232.34b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 30, 2026
| Earnings per share (EPS) | 1.27k |
| Gross Margin | 68.99% |
| Net Profit Margin | 25.01% |
| Debt/Equity Ratio | 5.5% |
How did RIG2 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/12 13:51 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gedeon Richter PLC is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Simon Mather | Barclays |
| Patrick Andrew Wood | BofA Global Research |
| Gabor Bukta | ConCorde Securities Ltd. |